CAS NO: | 2244864-88-6 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | Sitravatinib malate (MGCD516 malate) is an orally bioavailablereceptor tyrosine kinase (RTK)inhibitor withIC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT,FLT3,DDR2,DDR1,TRKA,TRKB, respectively[1]. Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity ofPD-1blockade through promoting an antitumor immune microenvironment[2]. | |||||||||||
IC50& Target[1] |
| |||||||||||
体外研究 (In Vitro) | Sitravatinib (0.01 nM-10 μM; 14 days) reduces colony formation in a dose-dependent manner in KLN205 and E0771 cell lines[2]. Cell Viability Assay[2]
| |||||||||||
体内研究 (In Vivo) | Sitravatinib (20 mg/kg; p.o.; once per day for 6 days) significantly inhibits tumor progression and induces tumor regression in C57BL/6 mice bearing CT1B-A5 cells model[2].
| |||||||||||
Clinical Trial | ||||||||||||
分子量 | 763.76 | |||||||||||
Formula | C37H35F2N5O9S | |||||||||||
CAS 号 | 2244864-88-6 | |||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | |||||||||||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |